|
Pluristem Appoints Ms. Chaya Mazouz Clinical
Operations Director
Monday August 4, 7:00 am ET |
|
|
NEW YORK--(BUSINESS
WIRE)--Pluristem Therapeutics Inc.
(NasdaqCM:PSTI); (DAX:PJT), a bio-therapeutics
company dedicated to the commercialization of
unrelated donor-patient (allogeneic) cell therapy products for a variety of degenerative, ischemic
and autoimmune indications, announced today that
Ms. Chaya Mazouz was appointed the Company’s
Clinical Operations Director.
Ms. Chaya Mazouz has extensive
experience in planning and managing clinical and
regulatory activities (Phase I to Phase III) for
drugs, devices and cell products. Ms. Mazouz
previously held the position of Clinical
Operations Director for a clinical-stage
biopharmaceutical company (Medgenics) involving
gene therapy, where she engineered Phase I/II
clinical studies. Prior to that, she served as
Clinical Manager for a drug delivery company
(TransPharma Medical) where she was responsible
for managing all of the company’s
clinical activities. In previous positions, Ms.
Mazouz led a multi-center Phase II study for a
pharmaceutical company (Pharmos Ltd.), and was
CRA and Project Manager at a startup company
engaged in gene discovery (IDgene).
Zami Aberman, Pluristem’s
President and CEO said: "We are proud that Ms.
Mazouz has joined our experienced team and
believe she will be highly successful in leading
the support and planning process for all our
future human clinical studies."
About Pluristem
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the
commercialization of non-personalized
(allogeneic) cell therapy products for the
treatment of several severe degenerative,
ischemic and autoimmune disorders. The Company
is developing a pipeline of products, stored
ready-to-use, that are derived from human
placenta, a non-controversial, non-embryonic,
adult stem cell source.
These placental mesenchymal
stromal cells (MSCs) are expanded in the
Company's proprietary PluriXTM
3D bioreactor, which imitates the natural
microstructure of bone marrow and does not
require supplemental growth factors or other
exogenous materials. Pluristem believes that the
resultant PLX (PLacental eXpanded) cells are
multi-potent and able to differentiate into a
variety of cell types. Recent evidence also
suggests their efficacy may be related to the
secretion of cytokines or other potent immune
modulators. Furthermore, PLX cells are immune
privileged and have immunomodulatory properties,
thus protecting the recipient from immunological
reactions that often accompany transplantations.
Pluristem's first product in
development, PLX-PAD, is intended to improve the
quality of life of millions of people suffering
from peripheral artery disease (PAD). The
Company's products in development also include
PLX-BMT, targeting the global shortfall of
matched tissue for bone marrow transplantation
(BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in
umbilical cord blood; PLX-STROKE, targeting
ischemic stroke; PLX-MS, targeting Multiple
Sclerosis; and PLX-IBD, targeting Inflammatory
Bowel Disease (IBD), which includes Crohn’s
disease and Ulcerative Colitis.
Pluristem has offices in the USA
with research and manufacturing facilities in
Israel.
See our product animation on
YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of
the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and
federal securities laws. These forward-looking
statements are based on the current expectations
of the management of Pluristem only, and are
subject to a number of factors and uncertainties
that could cause actual results to differ
materially from those described in the
forward-looking statements. For example, when we
say that we believe Ms. Mazouz will be highly
successful in leading the support and planning
process for all our future human clinical
studies, we are using a forward-looking
statement. The following factors, among others,
could cause actual results to differ materially
from those described in the forward-looking
statements: changes in technology and market
requirements; our technology may not be
validated as we progress further and our methods
may not be accepted by the scientific community;
we may be unable to retain or attract key
employees whose knowledge is essential to the
development of our products; unforeseen
scientific difficulties may develop with our
process; results in the laboratory may not
translate to equally good results in real
surgical settings; our patents may not be
sufficient ;our products may harm recipients;
changes in legislation; inability to timely
develop and introduce new technologies, products
and applications; loss of market share and
pressure on pricing resulting from competition,
which could cause the actual results or
performance of Pluristem to differ materially
from those contemplated in such forward-looking
statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly
release any revisions to these forward-looking
statements to reflect events or circumstances
after the date hereof or to reflect the
occurrence of unanticipated events. For a more
detailed description of the risk and
uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to
time with the Securities and Exchange
Commission.
For more information visit our
website at
www.pluristem.com, the content of which is
not part of this press release.
Contact:
Pluristem
William Prather RPh, MD, 303-883-4954 (Investors)
Sr. VP Corporate Development
bill@pluristem.com
Source:
Pluristem Therapeutics Inc.
|
|
|
|
